Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Single dose of PF-07220060 as first Tablet Formulation
Single dose of PF-07220060 as first Formulation · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Participants will receive PF-07220060 tablet by mouth |
| Cohort 2 | EXPERIMENTAL | Participants will receive PF-07220060 tablet by mouth |
| Cohort 3 | EXPERIMENTAL | Participants will receive PF-07220060 tablet by mouth |
| Cohort 4 | EXPERIMENTAL | Participants will receive PF-07220060 tablet by mouth |
| Cohort 5 | EXPERIMENTAL | Participants will receive PF-07220060 tablet by mouth |
| Cohort 6 | EXPERIMENTAL | Participants will receive PF-07220060 and Rabeprazole tablets by mouth |
| Cohort 7 | EXPERIMENTAL | Participants will receive PF-07220060 and Rabeprazole tablet by mouth |
| Cohort 8 | EXPERIMENTAL | Participants will receive PF-07220060 tablet by mouth |
| Name | Type | Description |
|---|---|---|
| Single dose of PF-07220060 as first Tablet Formulation | DRUG | A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions. |
| Single dose of PF-07220060 as second Tablet Formulation | DRUG | A single dose of PF-0720060 as the second Tablet Formulation administered under fasting conditions |
| Single dose of PF-07220060 as a Tablet Formulation | DRUG | A single dose of PF-07220060 as a tablet formulation administered under fed conditions |
| Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration | DRUG | A 2-treatment fixed sequence of single dose of PF-07220060 tablets under fasting conditions followed by a single dose of PF-07220060 tablets under Proton Pump Inhibitor (PPI) administration under fasting condition (following a 7 day oral rabeprazole tablets daily administration). |
| Single dose of PF-07220060 as third tablet formulation | DRUG | A 2-period randomized 2-sequence cross over of a single dose of PF-07220060 as first and third tablet formulation under fasting conditions with a 6-day washout in between them |
Inclusion Criteria: * Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring * BMI of 17.5-30.5 kg/m2; and a total body weight \>50 kg (110 lb). * Evidence of a personally sig...
A single dose of PF-07220060 as first formulation refers to an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It was evaluated in a Phase 1 study of healthy adult participants, comparing multiple tablet forms of the study medicine. The drug remains in clinical development and is not approved.
PF-07220060 is made by Pfizer, Inc., which trades under the ticker PFE. Pfizer conducted the Phase 1 study of the first tablet formulation of PF-07220060 in healthy adults. The compound is an investigational small molecule and has not been approved for any indication.
PF-07220060 is in Phase 1 development. The single completed trial, NCT05923411, was a Phase 1 study of multiple tablet forms of the study medicine in healthy adults. Because only Phase 1 testing has been reported, PF-07220060 is investigational and has not received FDA approval.
PF-07220060 has been studied in one clinical trial, NCT05923411, titled A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults. The Phase 1 trial was completed, enrolled 113 participants, was randomized and controlled, and took place in the United States.
Yes. A single dose of PF-07220060 as first formulation is also known as a single dose of PF-07220060 as first tablet formulation. Both names refer to the same investigational small molecule from Pfizer, Inc. (ticker PFE) that was tested in the Phase 1 trial NCT05923411.
The Phase 1 trial NCT05923411 studied multiple tablet forms of PF-07220060 in healthy adult participants. It enrolled 113 participants, was randomized and controlled, and was completed. Participants were 18 years or older, of any sex, and the trial was conducted in the United States.